Skip to main content
NewslettersWatchlist

Cyclo Therapeutics Inc(CYTH-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

Cyclo Therapeutics to Present at the Virtual Investor 2023 Companies to Watch Event

Business Wire - Tue Jan 10, 2023

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that N. Scott Fine, Chief Executive Officer of Cyclo Therapeutics will present at the Virtual Investor 2023 Companies to Watch Event on Thursday, January 19, 2023 at 11:00 AM ET.

A live video webcast of the presentation will be available on the Events page of the Investors section of the Company’s website (cyclotherapeutics.com). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.

About Cyclo Therapeutics

Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with disease. The Company’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is the subject of four formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease, (www.ClinicalTrials.govNCT02939547, NCT02912793, NCT03893071 and NCT04860960). The Company is conducting a Phase 2b clinical trial using Trappsol® Cyclo™ intravenously in early Alzheimer’s disease (NCT05607615) based on encouraging data from an Expanded Access program for Alzheimer’s disease (NCT03624842). Additional indications for the active ingredient in Trappsol® Cyclo™ are in development. For additional information, visit the Company’s website: www.cyclotherapeutics.com.

Provided Content: Content provided by Business Wire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe

inside the market
Advantage Energy director buys as stock rallies
Ted Dixon
market news
The close: S&P 500 higher but TSX slips as traders await key U.S. inflation data
Traders work on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., May 8, 2024. REUTERS/Brendan McDermid/File Photo
opinion
You’ve heard of dollar-cost averaging. How about trying dollar-cost selling?
Nancy Woods
market news
The close: Dow up seven in a row as jobs data boosts rate-cut hopes; TSX at new record high
NEW YORK, NEW YORK - MAY 03: Traders work on the floor of the New York Stock Exchange (NYSE) on May 03, 2024 in New York City. The Dow surged over 400 points in morning trading as new economic numbers showed that the central bank may cut interest rates sooner than expected. (Photo by Spencer Platt/Getty Images)
watchlist
25 stocks most added to Watchlists
market news
The close: TSX gives up winning streak as Shopify posts record decline
A trader works on the trading floor at the New York Stock Exchange (NYSE) in New York City, U.S., April 5.
market news
The close: S&P 500 and TSX extend winning streaks, despite Disney drag
A specialist trader works at his post on the floor at the New York Stock Exchange (NYSE) on April 29.
inside the market
How pro money managers are balancing exposure to Canadian and U.S. stocks
Rob Carrick

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).